Webinar Wednesday: Overcome Biomarker Multiplexing Challenges in Drug Development
Paul Rhyne from BDS Shares Recommended Multiplexing Techniques
Paul Rhyne, PhD, Chief Scientific Officer at Biologic Development Services (BDS), shares insights from a review article co-authored with 11 colleagues from pharmaceutical companies, clinical research organizations (CRO), and government agencies over two years titled: Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development.
Continue Reading >
xMAP Technology makes up the basis of Luminex’s core business. This flexible technology is centered on the use of Luminex xMAP Microspheres.